ClinicalTrials.gov
ClinicalTrials.gov Menu

Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01711554
Recruitment Status : Suspended (Scheduled interim monitoring)
First Posted : October 22, 2012
Last Update Posted : April 24, 2018
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Suspended
  Estimated Primary Completion Date : December 31, 2018
  Study Completion Date : No date given